2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Genitourinary
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
63
Precursor Cell Lymphoblastic Leukemia-Lymphoma
52
Leukemia, Myeloid, Chronic-Phase
34
Leukemia
30
Leukemia, Myeloid, Acute
18
Breast Neoplasms
18
Recurrence
15
Prostatic Neoplasms
14
Leukemia, Lymphocytic, Chronic, B-Cell
13
Neoplasm Metastasis
12
Blast Crisis
12
Multiple Myeloma
11
Carcinoma, Non-Small-Cell Lung
11
Burkitt Lymphoma
11
Pancreatic Neoplasms
10
Neoplasms
9
Leukemia, Myeloid, Accelerated Phase
9
Lung Neoplasms
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Non-Hodgkin
7
Glioblastoma
7
Melanoma
6
Lymphoma
6
Glioma
6
Rectal Neoplasms
5
Philadelphia Chromosome
5
Ovarian Neoplasms
5
Myelodysplastic Syndromes
5
Lymphoma, Large B-Cell, Diffuse
5
Hematologic Neoplasms
5
Interventions
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
testosterone undecanoate
1
tempol
1
TEMPOL-H
1
Sirolimus
1
Nelfinavir
1
Metformin
1
Hydroxychloroquine
1
Gonadotropins
1
Diet, Protein-Restricted
1
Dasatinib
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostate Cancer Recurrent
×
Dasatinib
×
Clear all
NCT05036226
2026-05-13
COAST
Medical University of South Carolina
Phase 1/2
Recruiting
76 enrolled